tax reform save day new tp vs
tax surpris upsid help off-set lower expect
revenu guidanc expect compani announc
addit buy-back author report
guidanc market close today top line line vs
consensu bottom line lower vs consensu
specif neulasta prolia enbrel beat consensu rest
portfolio in-lin lower consensu think prolia continu
show strong growth sale beat consensu quarter
yoy growth guidanc top-line rang
consensu estim vs bottom line rang
line better consensu number due lower tax rate notabl tax
reform lower non- tax rate
previous potenti sustain level also author
share repurchas program start soon next week
acceler share buy-back lower share count also favor
bottom line number new sale estim vs
previous non-ep vs due lower share count
tax rate
risk thesi includ commerci setback repatha aimovig
closer biosimilar risk new ep
vs respect
valuat metric
number share
price month
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
biotechnolog compani engag
develop manufactur wide rang therapeut
unit state intern
price feb rate neutral target price analyst alethia young
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
cash-flow financ activ
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
 close
scenario associ peak sale
repatha tri repres would
happen abl block regeneron/sanofi praulent
market
grey scenario associ peak sale
repatha tri repres would
happen outcom result under-perform expect term
abil acceler script write payer approv
focu remain signific cash leverag potenti could
transform potenti extern deal around oversea cash
repatri one key question call capit alloc plan
drive growth buy-back potenti
pay debt think strong financi leverag
deal differ size focus therapeut area includ
bone health cardiovascular oncolog inflamm neurosci howev
sound like compani disciplin overpay deal
aimovig erenumab migrain remain biggest growth opportun
potenti first market cgrp antibodi space
advantag time market price negoti term mechan action
aimovig monoclon antibodi target cgrp receptor instead
ligand enabl lower concentr antibodi requir block signal
pathway howev phase data view similar differ
competitor commerci execut import race domin
player estim sale aimovig
term potenti base busi headwind focus
potenti biosimilar risk neulasta sensipar compani comment
rang top-line guidanc wider usual uncertainti
around sensipar gener entri talk compani post call next
import event decis pediatr exclus next monday
compani trial march three day patent expir
date march abl get pediatr exclus extens
anoth month time gener threat
earlier stage pipelin opportun could becom interest
valuat mutein long-act
bite oncolog program think sever earli stage asset look
interest could synergi pipelin phase
studi distinct mechan action cgrp think data
posit combin aimovig could potenti differenti
compani cgrp asset mutein
select stimul regulatori cell auto immun diseas think moa
make lot sens interest see data lastli amgen
sever half-lif extend bite program preclin phase stage
although earli think potenti show better profil blincyto
could also work solid tumor
compani mention price
